首先逐渐减少传统合成改善病情抗风湿药（csDMARD）或肿瘤坏死因子抑制剂（TNFi）：抗环瓜氨酸肽抗体（ACPA）阳性或阴性类风湿关节炎发作的风险是否不同？ - Suppr

Suppr

超能文献

Tapering csDMARD or TNFi first: is the risk of flares different for ACPA-positive or ACPA-negative rheumatoid arthritis?

作者信息

Heutz Judith W, Looijen Agnes E M, van der Helm-van Mil Annette H M, de Jong Pascal H P, van Mulligen Elise

机构信息

Department of Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands

Department of Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands.

出版信息

RMD Open. 2024 Jul 20;10(3):e004258. doi: 10.1136/rmdopen-2024-004258.

DOI:10.1136/rmdopen-2024-004258

PMID:39032947

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11261664/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b999/11261664/3e2db545067b/rmdopen-10-3-g001.jpg

相似文献

Tapering csDMARD or TNFi first: is the risk of flares different for ACPA-positive or ACPA-negative rheumatoid arthritis?首先逐渐减少传统合成改善病情抗风湿药（csDMARD）或肿瘤坏死因子抑制剂（TNFi）：抗环瓜氨酸肽抗体（ACPA）阳性或阴性类风湿关节炎发作的风险是否不同？

RMD Open. 2024 Jul 20;10(3):e004258. doi: 10.1136/rmdopen-2024-004258.

Association between seropositivity and discontinuation of tumor necrosis factor inhibitors due to ineffectiveness in rheumatoid arthritis.类风湿关节炎中因疗效不佳导致肿瘤坏死因子抑制剂停药与血清阳性的相关性。

Clin Rheumatol. 2019 Oct;38(10):2757-2763. doi: 10.1007/s10067-019-04626-x. Epub 2019 Jun 10.

The impact of autoantibodies on the efficacy of biological disease-modifying anti-rheumatic drugs in rheumatoid arthritis: meta-analysis of randomized controlled trials.自身抗体对类风湿关节炎中生物性病情改善抗风湿药物疗效的影响：随机对照试验的荟萃分析

Rheumatology (Oxford). 2025 Feb 1;64(2):548-560. doi: 10.1093/rheumatology/keae113.

Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study.在类风湿关节炎患者达到疾病控制后，逐渐减少 TNF 抑制剂与传统合成 DMARDs 的剂量：随机对照 TARA 研究的第一年结果。

Ann Rheum Dis. 2019 Jun;78(6):746-753. doi: 10.1136/annrheumdis-2018-214970. Epub 2019 Apr 6.

Presence of anti-cyclic citrullinated peptide antibodies is associated with better treatment response to abatacept but not to TNF inhibitors in patients with rheumatoid arthritis: a meta-analysis.抗环瓜氨酸肽抗体的存在与类风湿关节炎患者对阿巴西普治疗反应的改善相关，但与 TNF 抑制剂无关：一项荟萃分析。

Clin Exp Rheumatol. 2020 May-Jun;38(3):455-466. Epub 2019 Nov 16.

Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial.在已确诊的类风湿关节炎中逐渐减少至无 DMARD 缓解：TARA 试验的 2 年结果。

Ann Rheum Dis. 2020 Sep;79(9):1174-1181. doi: 10.1136/annrheumdis-2020-217485. Epub 2020 Jun 1.

Presence of anti-citrullinated protein antibodies and costs and disease activity in early rheumatoid arthritis - a 3-year follow-up.抗瓜氨酸化蛋白抗体的存在与早期类风湿关节炎的费用和疾病活动度——一项 3 年随访研究。

Scand J Rheumatol. 2020 Sep;49(5):379-388. doi: 10.1080/03009742.2020.1750688. Epub 2020 Jul 20.

Two-year cost effectiveness between two gradual tapering strategies in rheumatoid arthritis: cost-utility analysis of the TARA trial.两种逐渐减量策略在类风湿关节炎中的两年成本效益比较：TARA 试验的成本效用分析。

Ann Rheum Dis. 2020 Dec;79(12):1550-1556. doi: 10.1136/annrheumdis-2020-217528. Epub 2020 Sep 9.

Efficacy predictors of a second tumor necrosis factor inhibitor in the treatment of rheumatoid arthritis.第二种肿瘤坏死因子抑制剂治疗类风湿关节炎的疗效预测因素

Medicine (Baltimore). 2020 Aug 28;99(35):e21827. doi: 10.1097/MD.0000000000021827.

Abatacept versus tumor necrosis factor inhibitors on mortality and medical utilizations in the treatment of rheumatoid arthritis associated interstitial lung disease: a large-scale real-world retrospective cohort study.阿巴西普与肿瘤坏死因子抑制剂治疗类风湿关节炎相关间质性肺病的死亡率和医疗利用比较：一项大规模真实世界回顾性队列研究。

Clin Exp Med. 2024 Aug 12;24(1):186. doi: 10.1007/s10238-024-01448-3.

本文引用的文献

Factors Associated With Maintenance of Remission Following Change From Combination Therapy to Monotherapy in Patients With Rheumatoid Arthritis.类风湿关节炎患者从联合治疗转换为单药治疗后病情缓解维持的相关因素

J Rheumatol. 2023 Sep;50(9):1114-1120. doi: 10.3899/jrheum.2022-1008. Epub 2023 Apr 15.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.EULAR 推荐的类风湿关节炎治疗方案：使用合成和生物疾病修正抗风湿药物：2022 更新版。

Ann Rheum Dis. 2023 Jan;82(1):3-18. doi: 10.1136/ard-2022-223356. Epub 2022 Nov 10.

Methotrexate prolongs TNF inhibitor survival, but only in autoantibody-positive rheumatoid arthritis: a validation study.甲氨蝶呤可延长肿瘤坏死因子抑制剂的疗效，但仅在自身抗体阳性的类风湿性关节炎中有效：一项验证性研究。

Ann Rheum Dis. 2023 Oct;82(10):e217. doi: 10.1136/annrheumdis-2020-219499. Epub 2021 Jan 13.

Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission.依那西普或甲氨蝶呤停药治疗持续缓解的类风湿关节炎患者。

Arthritis Rheumatol. 2021 May;73(5):759-768. doi: 10.1002/art.41589. Epub 2021 Mar 24.

Ann Rheum Dis. 2020 Sep;79(9):1174-1181. doi: 10.1136/annrheumdis-2020-217485. Epub 2020 Jun 1.

Methotrexate reduces withdrawal rates of TNF inhibitors due to ineffectiveness in rheumatoid arthritis but only in patients who are seropositive.甲氨蝶呤可降低类风湿关节炎患者中因肿瘤坏死因子抑制剂无效而导致的停药率，但仅在血清学阳性患者中有效。

Ann Rheum Dis. 2020 Nov;79(11):1516-1517. doi: 10.1136/annrheumdis-2020-217725. Epub 2020 May 28.

Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment.在逐渐减少改善病情抗风湿药（DMARD）治疗的类风湿关节炎患者中，通过多种生物标志物疾病活动度和自身抗体状态预测疾病复发

Ann Rheum Dis. 2016 Sep;75(9):1637-44. doi: 10.1136/annrheumdis-2015-207900. Epub 2015 Oct 19.

Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study.稳定缓解的类风湿关节炎患者在减少或停止抗风湿治疗时的复发率：前瞻性随机对照 RETRO 研究的中期结果。

Ann Rheum Dis. 2016 Jan;75(1):45-51. doi: 10.1136/annrheumdis-2014-206439. Epub 2015 Feb 6.

Developing a construct to evaluate flares in rheumatoid arthritis: a conceptual report of the OMERACT RA Flare Definition Working Group.开发评估类风湿关节炎 flares 的指标：OMERACT RA Flare Definition 工作组的概念报告。

J Rheumatol. 2011 Aug;38(8):1745-50. doi: 10.3899/jrheum.110400.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验